Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

Christopher P CannonRichard PratleySamuel Dagogo-JackJames MancusoSusan HuyckUrszula MasiukiewiczBernard CharbonnelRobert FrederichSilvina GalloFrancesco CosentinoWeichung J ShihIra GantzSteven G TerraDavid Z I CherneyDarren K McGuirenull null

Published in: The New England journal of medicine (2020)

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).

Keyphrases

cardiovascular events
cardiovascular disease
type diabetes
coronary artery disease
glycemic control
cardiovascular risk factors
double blind
phase iii
insulin resistance
emergency department
metabolic syndrome
clinical trial
study protocol
skeletal muscle
drug induced